BioXcel Therapeutics, Inc. — Revenue by Fiscal Year
4 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/edd47281-6bb8-45e8-a059-0bbe6c28bd97/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $642.0k | 2025-01-01 – 2025-12-31 | evidence 0001104659-26-036214 |
| FY 2024 | $2.3M | 2024-01-01 – 2024-12-31 | evidence 0001558370-25-003985 |
| FY 2023 | $1.4M | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-003784 |
| FY 2022 | $375.0k | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-003940 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
BioXcel Therapeutics, Inc. — all facts · Net Income · Operating Income